Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: January 23 at 6:53:16 PM EST Loading Chart for CAPR ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

Check the time stamp on this data. Updated AI-Generated Signals for Capricor Therapeutics Inc. (CAPR) available here: CAPR.

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease progression.

TD Cowen analyst Ritu Baral maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17. Uy Ear has given his Hold rating due to a combination of factors surrounding ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...